Abstracts tagged "Scleroderma"

Abstract Number: 1168 • ACR Convergence 2020
Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma
Suzanne Li¹, Mara Becker², Sandy Hong³, Polly Ferguson⁴, Themba Nyrienda¹, Tracy Andrews⁵, Katie Stewart⁶, C. Egla Rabinovich⁷, Robert Fuhlbrigge⁸, Thomas Mason⁹, Elena Pope¹⁰, Maria Ibarra¹¹, Fatma Dedeoglu¹², Gloria Higgins¹³, Ronald Laxer¹⁴, Marilynn Punaro⁶, Kathryn Torok¹⁵ and CARRA Investigators¹⁶, ¹Hackensack University Medical Center, Hackensack, ²Duke University School of Medicine, Durham, NC, ³University of Iowa Stead Family Children's Hospital, Iowa City, IA, ⁴University of Iowa Carver College of Medicine, Iowa City, IA, ⁵Rutgers, Newark, ⁶UT Southwestern, Dallas, TX, ⁷Duke University Hospital, Durham, NC, ⁸University of Colorado, Denver, CO, ⁹Mayo Clinic, Rochester, MN, ¹⁰Hospital For Sick Kids, Toronto, ON, Canada, ¹¹Children's Mercy Kansas City, Kansas City, MO, ¹²Boston Children's Hospital, Boston, MA, ¹³Nationwide Childrens Hospital/ The Ohio State University, Columbus, OH, ¹⁴The Hospital for Sick Children, Toronto, ON, Canada, ¹⁵University of Pittsburgh, Pittsburgh, PA, ¹⁶CARRA, Durham
Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease. Treatment is directed towards controlling disease activity to minimize risk for functional impairment…
Abstract Number: 1914 • ACR Convergence 2020
Long Non-coding RNA HOTAIR Induces GLI2 Expression Through Notch Signalling in Systemic Sclerosis Dermal Fibroblasts
Christopher Wasson¹, Rebecca Ross¹, Rebecca Wells¹, Clarissa Corinaldesi¹, Ioanna Georgiou², Natalia Riobo-Del Galdo² and Francesco Del Galdo³, ¹1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, ²2. School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is characterised by tissue fibrosis of the major organs of the body including the skin, lungs and heart. We have previously…
Abstract Number: 0912 • ACR Convergence 2020
Effectiveness of DETECT Algorithm in Japanese Systemic Sclerosis Patients with Old or New Hemodynamic Definition of Pulmonary Arterial Hypertension
Takanori Ito¹, Takehiro Nakai², Genki Kidoguchi², Sho Fukui², Hiroki Ozawa², Satoshi Kawaai², Yukihiko Ikeda², Hisanori Shimizu², Yasuhiro Suyama³, Atsushi Nomura², Hiromichi Tamaki¹, Kenichi Yamaguchi² and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ³JR Tokyo General Hospital, Tokyo, Japan
Background/Purpose: Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) has been known as a life-threatening manifestation in SSc. Earlier detection and subsequent interventions are important to improve…
Abstract Number: 1169 • ACR Convergence 2020
Three-Dimensional Analysis of Facial Asymmetry in Craniofacial Scleroderma
Daniel Glaser¹, Christopher Liu² and Kathryn Torok³, ¹UPMC Children's Hospital of Pittsburgh, Piitsburgh, PA, ²Children's Hospital of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Localized scleroderma (LS) is a rare, progressive autoimmune disease of the skin and underlying connective tissue that can result in devastating functional impairment and cosmetic damage in children. …
Abstract Number: 1915 • ACR Convergence 2020
Leptin Plays a Critical Role in Modulating Dermal Adipose Tissue, Inflammation and Skin Fibrosis
Roberta Goncalves Marangoni¹, Stacey Duemmel², Marc Nuzzo², Christopher Ritchlin³ and Benjamin Korman³, ¹University of Rochester Medical Center, Rochester, NY, ²Department of Medicine, University of Rochester Medical Center, Rochester, ³Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: We previously demonstrated that systemic sclerosis (SSc) patients have substantial reduction in dermal white adipose tissue (dWAT) which correlates with skin fibrosis. In animal…
Abstract Number: 0913 • ACR Convergence 2020
Systemic Sclerosis Portends a Higher Risk of Conduction and Rhythm Disorders at Diagnosis and During Disease Course: Results from a US Population Based Study
Yasser Radwan¹, Reto Kurmann², Avneek Singh Sandhu³, Edward El-Am⁴, Cynthia Crowson², Eric Matteson⁵, Thomas Osborn², Kenneth Warrington⁶, Rekha Mankad² and Ashima Makol², ¹Mayo Clinic, Rochester, Minnesota, USA, Lansing, MI, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Mayo Clinic, Rochester, Minnesota, USA, Dayton, OH, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, MN, ⁶Mayo Clinic, Rochester, MN
Background/Purpose: Cardiac involvement, including electrocardiogram (ECG) abnormalities, is associated with worse prognosis in systemic sclerosis (SSc). We studied the incidence, risk factors and outcomes of…
Abstract Number: 1170 • ACR Convergence 2020
Exploring the Use of Von Willebrand Factor as a Disease Biomarker in a Cohort of Patients with Juvenile Scleroderma: A Pilot Study
Natalia Vasquez-Canizares¹, Beamon Agarwal², Tamar Rubinstein³, Dawn Wahezi¹ and Morayma Reyes-Gil¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²GenomeRxUS LLC, Clifton Heights, PA, ³Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY
Background/Purpose: Juvenile Scleroderma (JScl) is a heterogenous disease characterized by autoimmunity, vasculopathy, and fibrosis. Morbidity and mortality remain high in part due to the continuing…
Abstract Number: 1991 • ACR Convergence 2020
Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Suzanne Li¹, Sarah Ishaq², Mary Buckley³, Kathryn Torok⁴, Barbara Edelheit⁵, Kaleo Ede⁶, Christopher Liu⁷ and C. Egla Rabinovich⁸, ¹Hackensack University Medical Center, Hackensack, ²Montclair State University, Montclair, ³Duke University, Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Conneticut Children's Medical Center, Hartford, ⁶Phoenix Children's Hospital, Phoenix, AZ, ⁷U Pittsburgh, Pittsburgh, ⁸Duke University Hospital, Durham, NC
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
Abstract Number: 0175 • ACR Convergence 2020
Identifying Immuno-phenotypes in Juvenile Localized Scleroderma with RNA Sequencing
Christina Schutt¹, Emily Mirizio², Kaila Schollaert-Fitch², Claudia Salgado³, Miguel Reyes-Mugica³ and Kathryn Torok², ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Medical Center, Pittsburgh
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease of the skin and underlying tissue characterized by an early inflammatory infiltrate followed by fibrosis and…
Abstract Number: 0915 • ACR Convergence 2020
Clinical Bedside Tools to Assess Systemic Sclerosis Vasculopathy: Can Digital Thermal Monitoring and Sublingual Microscopy Identify Patients with Current or past Digital Ulcers?
Tracy Frech¹, Zhining Ou², Julie Thomas² and Angela Presson², ¹University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT
Background/Purpose: Sublingual microscopy is reported as a useful tool for vasculopathy assessment in SSc. Digital thermal monitoring (DTM) correlates with flow-mediated dilatation, and may identify…
Abstract Number: 1378 • ACR Convergence 2020
Understanding Diagnostic Pathways in Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Shervin Assassi¹, Nan Shao², Ziwei Yin², Elizabeth Volkmann³, Donald Zoz² and Thomas Leonard², ¹University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, ³University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of SSc. SSc-ILD is usually detected in a patient known to have SSc, but ILD may…
Abstract Number: 2018 • ACR Convergence 2020
Development and Validation of an Artificial Intelligence Approach for the Detection of Radiographic Sacroiliitis
Keno-Kyrill Bressem¹, Janis Vahldiek¹, Lisa Adams¹, Stefan Niehues¹, Hildrun Haibel¹, Valeria Rios Rodriguez¹, Murat Torgutalp¹, Mikhail Protopopov¹, Fabian Proft¹, Judith Rademacher¹, Joachim Sieper¹, Martin Rudwaleit², Bernd Hamm¹, Markus Makowski¹, Kay-Geert Hermann¹ and Denis Poddubnyy³, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany, ³Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Conventional radiography of the sacroiliac joints is still recommended as the first imaging method if axial spondyloarthritis (axSpA) is suspected. Furthermore, radiographic sacroiliitis is…
Abstract Number: 711 • 2019 ACR/ARP Annual Meeting
Ultrasound Evaluation of the Hands in Patients with Systemic Sclerosis: Osteophytosis Is a Major Contributor to Tender Joints
Robert Fairchild¹, Melody Chung ¹, Laurel Sharpless ¹, Shufeng Li ², Jison Hong ¹, Khushboo Sheth ¹ and Lorinda Chung ¹, ¹Stanford University, Palo Alto, CA, ²Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, CA
Background/Purpose: Systemic Sclerosis (SSc) is a progressive fibrotic and vascular disease with peripheral manifestations including arthritis, tendinopathy, sclerodactyly, contractures, calcinosis, acroosteolysis, and vascular disease which…
Abstract Number: 1057 • 2019 ACR/ARP Annual Meeting
Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma
Pei-Suen Tsou¹, Nicholas Flavahan ² and Dinesh Khanna ³, ¹University of Michigan, Ann Arbor, MI, ²The Johns Hopkins University School of Medicine, Baltimore, MD, ³Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence, University of Michigan, Ann Arbor
Background/Purpose: Iloprost improves Raynaud‘s phenomenon and digital ulcers in scleroderma (SSc) patients. This is hypothesized to reflect anti-platelet and vasodilatory effects. Different trials and cohorts…
Abstract Number: 1833 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial
Kristin Highland¹, Oliver Distler ², Masataka Kuwana ³, Yannick Allanore ⁴, Shervin Assassi ⁵, Arata Azuma ⁶, Arnaud Bourdin ⁷, Christopher Denton ⁸, Jörg Distler ⁹, Anna Maria Hoffmann-Vold ¹⁰, Dinesh Khanna ¹¹, Maureen Mayes ⁵, Ganesh Raghu ¹², Madelon Vonk ¹³, Martina Gahlemann ¹⁴, Mannaig Girard ¹⁵, Susanne Stowasser ¹⁶, Donald Zoz ¹⁷, Aryeh Fischer ¹⁸ and Toby Maher ¹⁹, ¹Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ⁴Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁶Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ⁷PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214 and Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, Montpellier, France, Montpellier, ⁸University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ⁹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ¹⁰Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ¹¹Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ¹²University of Washington, Seattle, USA, Seattle, ¹³Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ¹⁴Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹⁵Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ¹⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ¹⁸University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ¹⁹National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the annual rate of decline in forced vital capacity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].